REGN
XNASREGENERON PHARMACEUTICALS
2 news · 90d
0 news · vs previous 7d (—)
Acceleration —
Tickers that have appeared in the same news over the last 90 days. Descriptive of past co-mention — not a recommendation.
Daily digest
Track $REGN sentiment without checking the page.
Top-discussed tickers and the AI sentiment we read. Not advice.
News · 2
How did the price react? →- Eli Lilly's new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims
Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.
- Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
Eli Lilly shares fell as its obesity drug Foundayo showed a weaker early commercial trajectory compared to oral Wegovy, while Novo Nordisk shares climbed on the contrast. Regeneron announced a drug pricing deal, and two unspecified companies disclosed leadership changes. The FDA also announced plans to issue vouchers related to psychedelic treatments.